TPN729MA
Modify Date: 2024-01-16 09:29:33
TPN729MA structure
|
Common Name | TPN729MA | ||
|---|---|---|---|---|
| CAS Number | 1422955-52-9 | Molecular Weight | 632.73 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C29H40N6O8S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of TPN729MATPN729MA (TPN729 maleate) is a selective phosphodiesterase type 5 (PDE5) inhibitor with an IC50 value of 2.28 nM. TPN729MA affects erectile function and it can be used for the research of erectile dysfunction[1]. |
| Name | TPN729MA |
|---|
| Description | TPN729MA (TPN729 maleate) is a selective phosphodiesterase type 5 (PDE5) inhibitor with an IC50 value of 2.28 nM. TPN729MA affects erectile function and it can be used for the research of erectile dysfunction[1]. |
|---|---|
| Related Catalog | |
| Target |
PDE5:2.28 nM (IC50) PDE6:45.2 nM (IC50) PDE1:566 nM (IC50) PDE4:834 nM (IC50) PDE11:6090 nM (IC50) |
| In Vivo | TPN729MA (1.25，2.5，5.0 mg/kg；1 次) 在所有时间点 5.0 mg/kg 剂量下增加海绵内压/血压比值 (ICP/BP)，在 2.5 mg/kg 剂量下 75，90，105 和 120 分钟时增加海绵内压/血压比[1]。 TPN729MA (5.0 μg/kg；静脉注射，1 次) 显著升高公比格犬的海绵内压和海绵内压/血压比[1]。 Animal Model: Male Sprague-Dawley rats with corpora cavernosa complete exposure[1] Dosage: 1.25, 2.5 and 5.0 mg/kg Administration: Intraduodenal (i.d.) injection; 1.25, 2.5 and 5.0 mg/kg, once Result: Dose-dependently increased the maximum intracavernous pressure (ICP) and ICP/blood pressure (BP). |
| References |
| Molecular Formula | C29H40N6O8S |
|---|---|
| Molecular Weight | 632.73 |